ASSESSMENT OF SURROGATE MARKERS FOR CARDIOVASCULAR DISEASE IN FAMILIAL MEDITERRANEAN FEVER-RELATED AMYLOIDOSIS PATIENTS HOMOZYGOUS FOR M694V MUTATION IN MEFV GENE
dc.contributor.author | Sahin, Sezgin | |
dc.contributor.author | Romano, Micol | |
dc.contributor.author | Guzel, Ferhat | |
dc.contributor.author | Piskin, David | |
dc.contributor.author | Poddighe, Dimitri | |
dc.contributor.author | Sezer, Siren | |
dc.contributor.author | Kasapcopur, Ozgur | |
dc.contributor.author | Appleton, C. Thomas | |
dc.contributor.author | Yilmaz, Ilker | |
dc.contributor.author | Demirkaya, Erkan | |
dc.date.accessioned | 2023-04-28T10:33:33Z | |
dc.date.available | 2023-04-28T10:33:33Z | |
dc.date.issued | 2022 | |
dc.description.abstract | Cardiovascular disease (CVD) remains underestimated in familial Mediterranean feverassociated AA amyloidosis (FMF-AA).We aimed to compare early markers of endothelial dysfunction and atherosclerosis in FMF-AA with a homozygous M694V mutation (Group 1 = 76 patients) in the Mediterranean fever (MEFV) gene and in patients with other genotypes (Group 2 = 93 patients). Measures of increased risk for future CVD events and endothelial dysfunction, including flowmediated dilatation (FMD), pentraxin-3 (PTX3), and carotid intima-media thickness (cIMT), and fibroblast growth factor 23 (FGF23) as a marker of atherosclerotic vascular disease were compared between groups. The frequency of clinical FMF manifestations did not differ between the two groups apart from arthritis (76.3% in Group 1 and 59.1% in Group 2, p < 0.05). FMD was significantly lower in Group 1 when compared with Group 2 (MD [95% CI]: 0.6 [(0.89)–(0.31)]). cIMT, FGF23, and PTX3 levels were higher in Group 1 (cIMT MD [95% CI]: 0.12 [0.08–0.16]; FGF23 MD [95% CI]: 12.8 [5.9–19.6]; PTX3 MD [95% CI]: 13.3 [8.9–17.5]). In patients with FMF-AA, M694V homozygosity is associated with lower FMD values and higher cIMT, FGF23, and PTX3 levels, suggesting increased CVD risk profiles. These data suggest that a genotype–phenotype association exists in terms of endothelial dysfunction and atherosclerosis in patients with FMF-AA. | en_US |
dc.identifier.citation | Sahin, S., Romano, M., Guzel, F., Piskin, D., Poddighe, D., Sezer, S., Kasapcopur, O., Appleton, C. T. G., Yilmaz, I., & Demirkaya, E. (2022). Assessment of Surrogate Markers for Cardiovascular Disease in Familial Mediterranean Fever-Related Amyloidosis Patients Homozygous for M694V Mutation in MEFV Gene. Life, 12(5), 631. https://doi.org/10.3390/life12050631 | en_US |
dc.identifier.uri | http://nur.nu.edu.kz/handle/123456789/7045 | |
dc.language.iso | en | en_US |
dc.publisher | Life | en_US |
dc.rights | Attribution-NonCommercial-ShareAlike 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/3.0/us/ | * |
dc.subject | Type of access: Open Access | en_US |
dc.subject | familial Mediterranean fever | en_US |
dc.subject | M694V homozygosity | en_US |
dc.subject | AA amyloidosis | en_US |
dc.subject | cardiovascular disease | en_US |
dc.subject | flow-mediated dilatation | en_US |
dc.subject | carotid artery intima-media thickness | en_US |
dc.title | ASSESSMENT OF SURROGATE MARKERS FOR CARDIOVASCULAR DISEASE IN FAMILIAL MEDITERRANEAN FEVER-RELATED AMYLOIDOSIS PATIENTS HOMOZYGOUS FOR M694V MUTATION IN MEFV GENE | en_US |
dc.type | Article | en_US |
workflow.import.source | science |